Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00230789 · ClinicalTrials.gov registry record · Phase 4
Effect Of Detrol LA With Behavioral Intervention In Overactive Bladder Subjects Dissatisfied With Recent OAB Medication.
A Phase 4 study, sponsored by Pfizer's Upjohn has merged with Mylan to form Viatris.
- Completed
- Registry status
- Phase 4
- Development phase
- 417
- Enrollment target
NCT00230789: Completed Phase 4 study, sponsored by Pfizer's Upjohn has merged with Mylan to form Viatris.
NCT00230789 is a Phase 4 study that has completed, run by Pfizer's Upjohn has merged with Mylan to form Viatris. The registered enrollment target is 417 participants, below the 518-participant average among 9,235 other Phase 4 trials with a reported enrollment target (19% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00230789, a Phase 4 study, has completed, sponsored by Pfizer's Upjohn has merged with Mylan to form Viatris.
- COMPLETED
- Registry status
- Phase 4
- Development phase
- 417 participants
- Enrollment target
Study Summary
To evaluate the effect of tolterodine ER in conjunction with behavioral intervention on subject satisfaction in OAB subjects who were dissatisfied with their most recent antimuscarinic OAB medication therapy.
Interventions
- DRUG Tolterodine ER 4 mg QD
- BEHAVIORAL OAB Patient Behavioral Training Material
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 417 participants |
| Start Date | 2005-10 |
| Est. Completion | 2006-12 |
| Phase | Phase 4 |
What the finished NCT00230789 record still lists
NCT00230789 is an interventional study that assigns participants to a tested intervention. The registered 417 participants enrollment target is mid-sized for trials with a published cap, below the 518-participant average among 9,235 other Phase 4 trials with a reported enrollment target (19% lower).
The record links to 0 conditions, and to 2 interventions - of which Tolterodine ER 4 mg QD is the first listed.
NCT00230789 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT00230789 about?
NCT00230789 is a clinical study titled "Effect Of Detrol LA With Behavioral Intervention In Overactive Bladder Subjects Dissatisfied With Recent OAB Medication.". To evaluate the effect of tolterodine ER in conjunction with behavioral intervention on subject satisfaction in OAB subjects who were dissatisfied with their most recent antimuscarinic OAB medication therapy.
What is the current status of trial NCT00230789?
This trial is currently completed. It is a Phase 4 study. The enrollment target is 417 participants. The study started on 2005-10. Estimated completion is 2006-12.
What interventions are being tested in trial NCT00230789?
The interventions under investigation include: Tolterodine ER 4 mg QD (DRUG), OAB Patient Behavioral Training Material (BEHAVIORAL).
Who is sponsoring clinical trial NCT00230789?
This trial is sponsored by Pfizer's Upjohn has merged with Mylan to form Viatris, which has 158 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT00230789's enrollment target sits among peer trials
417 202nd of 2000 higher than 1,797 of 2,000 other Phase 4 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 4 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT06169735 · 417 participants · Phase 4
Does Fluorescence With or Without Indocyanine Green Improve Parathyroid Identification and Preservation
- NCT06699901 · 417 participants
Antibiotic Concentrations After MassivE Transfusion Study
- NCT03135886 · 418 participants · NA
Project I Test: Implementing HIV Testing in Opioid Treatment Programs
- NCT03527537 · 416 participants · Phase 4
Gestational Diabetes and Pharmacotherapy (GAP)
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia